OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The combination modulates serotonergic and dopaminergic pathways to treat depressive episodes in bipolar I disorder.
| Metabolism | Olanzapine: primarily metabolized by CYP1A2 and glucuronidation. Fluoxetine: extensively metabolized by CYP2D6 and CYP2C9 to active metabolite norfluoxetine. |
| Excretion | Olanzapine: ~57% renal (metabolites), ~30% fecal. Fluoxetine: ~80% renal (metabolites, mainly norfluoxetine), ~15% fecal. |
| Half-life | Olanzapine: 30 h (young adults); 50 h (elderly). Fluoxetine: 4-6 days (single dose), 4-6 days (norfluoxetine); longer with chronic dosing (up to 6-8 weeks to steady state). Clinical context: drug accumulates over weeks. |
| Protein binding | Olanzapine: 93% bound to albumin and α1-acid glycoprotein. Fluoxetine: 94-95% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Olanzapine: ~15 L/kg (extensive tissue distribution). Fluoxetine: 35 L/kg (extensive distribution, including brain). |
| Bioavailability | Olanzapine: ~60% oral (60% absorbed, extensive first-pass). Fluoxetine: >90% oral (well absorbed, minimal first-pass). |
| Onset of Action | Oral: 2-4 weeks for antidepressant/antipsychotic effect. Initial improvement may be seen within 1-2 weeks. |
| Duration of Action | Plasma levels sustained for days due to long half-life; clinical effect persists for weeks after discontinuation. Therapeutic levels maintained with once-daily dosing. |
| Molecular Weight | 364.89 |
| Action Class | Atypical Antipsychotic and Selective Serotonin Reuptake Inhibitor (SSRI) combination |
Olanzapine 6 mg / fluoxetine 25 mg orally once daily in the evening, with dose adjustments based on response and tolerability.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min), use with caution but no specific guidelines available. |
| Liver impairment | For Child-Pugh Class A or B: start olanzapine 5 mg / fluoxetine 20 mg once daily; for Child-Pugh Class C: avoid use due to lack of data and potential for reduced clearance. |
| Pediatric use | For children 10-17 years: initial dose olanzapine 2.5 mg / fluoxetine 10 mg orally once daily; titrate to usual range of olanzapine 6 mg / fluoxetine 25 mg once daily; maximum dose olanzapine 12 mg / fluoxetine 50 mg once daily. |
| Geriatric use | Initiate at olanzapine 3 mg / fluoxetine 20 mg orally once daily; increase slowly with close monitoring for orthostatic hypotension, extrapyramidal symptoms, and metabolic effects. |
| 1st trimester | Limited data; potential risk of neural tube defects and cardiac malformations with first trimester fluoxetine exposure. Olanzapine associated with increased risk of gestational diabetes and weight gain. Use only if benefit outweighs risk. |
| 2nd trimester | Continued caution; monitor for gestational diabetes, excessive weight gain, and fetal growth. Fluoxetine exposure associated with persistent pulmonary hypertension of the newborn (PPHN) when used after 20 weeks gestation. |
| 3rd trimester | Use in third trimester may cause neonatal withdrawal symptoms (irritability, feeding difficulties, respiratory distress) with fluoxetine; olanzapine may cause extrapyramidal symptoms or withdrawal. Monitor neonate for adaptation syndrome. |
Clinical note
CNS depressants may enhance sedative effects Can cause metabolic changes including weight gain hyperlipidemia and hyperglycemia.
| Placental transfer | Both cross the placenta. Fluoxetine and its active metabolite norfluoxetine achieve fetal concentrations approximating maternal plasma levels. Olanzapine crosses the placenta with a cord-to-maternal plasma ratio of approximately 0.7. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Olanzapine/fluoxetine is not approved for use in patients under 10 years of age.
| Common Effects | Dizziness Sleepiness Orthostatic hypotension sudden lowering of blood pressure on standing Dryness in mouth Weight gain Increased prolactin level in blood Constipation Muscle stiffness Restlessness Tremors |
| Serious Effects | Suicidal thoughts or behaviors (especially in children, adolescents, and young adults), Neuroleptic malignant syndrome (NMS), Tardive dyskinesia, Serotonin syndrome, Hyperglycemia and diabetes mellitus, Dyslipidemia, Weight gain, Orthostatic hypotension, Seizures, Leukopenia/neutropenia/agranulocytosis, QT prolongation, Pancreatitis, Hepatic failure |
Hypersensitivity to olanzapine or fluoxetineConcurrent use of MAOIs (monoamine oxidase inhibitors) or within 14 days of MAOI therapyConcurrent use of thioridazine or pimozide due to QT prolongation riskConcurrent use of linezolid or methylene blue intravenous administration
| Precautions |
Loading safety data…
| Breastfeeding | Both drugs are excreted into breast milk. Olanzapine has an estimated infant dose of 1-2% of maternal weight-adjusted dose; fluoxetine and its active metabolite norfluoxetine accumulate with long-term use. Monitor infant for sedation, poor feeding, and weight gain. Benefit should outweigh potential risks; consider alternative if infant is premature or has compromised hepatic function. |
| Lactation Rating | L3 (Moderately Safe) for olanzapine; L4 (Possibly Hazardous) for fluoxetine due to long half-life and active metabolite accumulation. |
| Teratogenic Risk | First trimester: Limited data; fluoxetine is a known SSRI associated with a small increased risk of cardiovascular malformations (primarily septal defects) with first-trimester exposure. Olanzapine has not shown a clear increase in major malformations, but data are limited. Second and third trimesters: SSRI exposure (fluoxetine) may increase risk of persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation syndrome (PNAS), including respiratory distress, feeding difficulties, irritability, and tremors. Third-trimester exposure to olanzapine may cause extrapyramidal symptoms and withdrawal in neonates. |
| Fetal Monitoring | Maternal: Monitor weight, blood glucose, lipids, and blood pressure due to metabolic risks of olanzapine; monitor for serotonin syndrome or neuroleptic malignant syndrome. Fetal/neonatal: Ultrasound for fetal growth and anatomy; neonatal monitoring for PNAS, extrapyramidal symptoms, and respiratory adaptation for at least 48 hours after delivery. |
| Fertility Effects | Olanzapine can cause hyperprolactinemia, potentially leading to menstrual irregularities, galactorrhea, and reduced fertility. Fluoxetine may cause sexual dysfunction but has not been consistently linked to impaired fertility. In men, olanzapine may reduce sperm quality. Overall, use may decrease fertility due to hormonal effects. |
| Suicidality: Monitor for worsening depression and suicidal thoughts, especially early in treatment, Metabolic changes: Hyperglycemia, dyslipidemia, weight gain, Extrapyramidal symptoms and tardive dyskinesia, Neuroleptic malignant syndrome (NMS), Serotonin syndrome, Hyperprolactinemia, Orthostatic hypotension, QT interval prolongation, Leukopenia/neutropenia, Seizures, Impaired cognitive and motor function |
| Food/Dietary | No specific food interactions. Grapefruit juice may increase fluoxetine levels (moderate interaction). Avoid excessive caffeine as it may exacerbate anxiety or insomnia. Take with food if gastrointestinal upset occurs. |
| Clinical Pearls | This combination is indicated for treatment-resistant depression (TRD) and bipolar I depression. Olanzapine's weight gain and metabolic effects are additive with fluoxetine. Monitor for serotonin syndrome, especially at initiation or dose changes. QT prolongation risk is higher due to both agents. Slow titration reduces orthostatic hypotension. Discontinue at least 5 weeks before MAOI initiation. |
| Patient Advice | Take once daily in the evening, without regard to meals. · May cause drowsiness, dizziness, or orthostatic hypotension; avoid driving until effects are known. · Report symptoms of serotonin syndrome (fever, muscle twitching, confusion) or neuroleptic malignant syndrome (fever, stiff muscles, altered mental status). · Monitor for worsening depression or suicidal thoughts, especially early in treatment. · Avoid alcohol and other CNS depressants. · Do not stop abruptly; taper under medical supervision to avoid withdrawal or rebound depression. · Inform all healthcare providers you are taking this medication. |